Survival and Chemotherapy Response in Metastatic Lung Carcinoids: Insights from the National Cancer Database.

Niraj Neupane, Sumeet K Yadav, Elham Moases Ghaffary, Scott R Houle, Umesh Ghimire, Binita Neupane, Sangharsha Thapa, Omid Mirmosayyeb, Zeni Kharel, Chengu Niu, Utsav Joshi
{"title":"Survival and Chemotherapy Response in Metastatic Lung Carcinoids: Insights from the National Cancer Database.","authors":"Niraj Neupane, Sumeet K Yadav, Elham Moases Ghaffary, Scott R Houle, Umesh Ghimire, Binita Neupane, Sangharsha Thapa, Omid Mirmosayyeb, Zeni Kharel, Chengu Niu, Utsav Joshi","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metastatic lung carcinoids (MLCs) represent a rare subset of lung cancers with distinct histologic subtypes. Survival outcomes and prognostic factors have not been well-studied in the real-world setting. This study investigates the impact of various treatments, including chemotherapy, hormonal therapy, and no treatment, on the overall survival (OS) of patients with typical and atypical MLC.</p><p><strong>Methods: </strong>Patients with MLC between 2010 and 2020 were included from the National Cancer Database based on histologic codes ICD-O-3 8240/3 and 8249/3. Kaplan-Meier curves and multivariate Cox proportional hazard regression were used to compare OS and evaluate prognostic factors.</p><p><strong>Results: </strong>The median age at diagnosis was 68 and 69 years for atypical and typical MLC, respectively. The 3-year OS for the atypical MLC cohort was 22.11%, and for typical MLC was 41.94% (P < 0.001). In the atypical MLC cohort, chemotherapy showed a nonsignificant benefit in OS (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.73-1.05; P = 0.21), whereas hormonal therapy was associated with significantly improved OS (HR, 0.72; 95% CI, 0.52-0.98; P =0.04). However, in the typical MLC cohort, chemotherapy was associated with adverse OS (HR, 2.15; 95% CI, 1.85-2.49; P < 0.0001), and hormonal treatment showed better, albeit nonsignificant OS (HR, 0.84; 95% CI, 0.67-1.05; P = 0.13).</p><p><strong>Conclusion: </strong>There is a notable difference in survival outcomes between typical and atypical MLC based on the treatment strategies. While hormonal therapy shows improvement in the OS, the effectiveness of chemotherapy varies depending on the histologic subtype. These findings emphasize the necessity for personalized therapeutic approaches based on the specific characteristics of MLC, ultimately contributing to improved patient outcomes in this challenging oncologic group. Further research is warranted to validate and expand upon these observations.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"14-20"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/oncology and stem cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-24-00001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Metastatic lung carcinoids (MLCs) represent a rare subset of lung cancers with distinct histologic subtypes. Survival outcomes and prognostic factors have not been well-studied in the real-world setting. This study investigates the impact of various treatments, including chemotherapy, hormonal therapy, and no treatment, on the overall survival (OS) of patients with typical and atypical MLC.

Methods: Patients with MLC between 2010 and 2020 were included from the National Cancer Database based on histologic codes ICD-O-3 8240/3 and 8249/3. Kaplan-Meier curves and multivariate Cox proportional hazard regression were used to compare OS and evaluate prognostic factors.

Results: The median age at diagnosis was 68 and 69 years for atypical and typical MLC, respectively. The 3-year OS for the atypical MLC cohort was 22.11%, and for typical MLC was 41.94% (P < 0.001). In the atypical MLC cohort, chemotherapy showed a nonsignificant benefit in OS (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.73-1.05; P = 0.21), whereas hormonal therapy was associated with significantly improved OS (HR, 0.72; 95% CI, 0.52-0.98; P =0.04). However, in the typical MLC cohort, chemotherapy was associated with adverse OS (HR, 2.15; 95% CI, 1.85-2.49; P < 0.0001), and hormonal treatment showed better, albeit nonsignificant OS (HR, 0.84; 95% CI, 0.67-1.05; P = 0.13).

Conclusion: There is a notable difference in survival outcomes between typical and atypical MLC based on the treatment strategies. While hormonal therapy shows improvement in the OS, the effectiveness of chemotherapy varies depending on the histologic subtype. These findings emphasize the necessity for personalized therapeutic approaches based on the specific characteristics of MLC, ultimately contributing to improved patient outcomes in this challenging oncologic group. Further research is warranted to validate and expand upon these observations.

转移性肺癌的生存和化疗反应:来自国家癌症数据库的见解。
背景:转移性肺类癌(MLCs)是一种罕见的肺癌亚型,具有不同的组织学亚型。在现实环境中,生存结果和预后因素尚未得到充分研究。本研究探讨了包括化疗、激素治疗和不治疗在内的各种治疗方法对典型和非典型MLC患者总生存期(OS)的影响。方法:根据组织编码ICD-O-3 8240/3和8249/3,从国家癌症数据库中纳入2010 - 2020年MLC患者。采用Kaplan-Meier曲线和多变量Cox比例风险回归比较OS和评估预后因素。结果:非典型MLC和典型MLC的中位诊断年龄分别为68岁和69岁。非典型MLC的3年OS为22.11%,典型MLC的3年OS为41.94% (P < 0.001)。在非典型MLC队列中,化疗对OS的益处不显著(风险比[HR], 0.89;95%置信区间[CI], 0.73-1.05;P = 0.21),而激素治疗与OS的显著改善相关(HR, 0.72;95% ci, 0.52-0.98;P = 0.04)。然而,在典型的MLC队列中,化疗与不良OS相关(HR, 2.15;95% ci, 1.85-2.49;P < 0.0001),激素治疗表现更好,但OS无显著性差异(HR, 0.84;95% ci, 0.67-1.05;p = 0.13)。结论:基于不同的治疗策略,典型和非典型MLC的生存结局存在显著差异。虽然激素治疗对OS有改善,但化疗的效果因组织学亚型而异。这些发现强调了基于MLC特定特征的个性化治疗方法的必要性,最终有助于改善这一具有挑战性的肿瘤组的患者预后。需要进一步的研究来验证和扩展这些观察结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信